0001246360-19-000766.txt : 20190225 0001246360-19-000766.hdr.sgml : 20190225 20190225175611 ACCESSION NUMBER: 0001246360-19-000766 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190221 FILED AS OF DATE: 20190225 DATE AS OF CHANGE: 20190225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: TOWSE MATTHEW W CENTRAL INDEX KEY: 0001195852 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51567 FILM NUMBER: 19630853 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NxStage Medical, Inc. CENTRAL INDEX KEY: 0001333170 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 043454702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 350 MERRIMACK STREET CITY: LAWRENCE STATE: MA ZIP: 01843 BUSINESS PHONE: 978-687-4700 MAIL ADDRESS: STREET 1: 350 MERRIMACK STREET CITY: LAWRENCE STATE: MA ZIP: 01843 4 1 form.xml PRIMARY DOCUMENT X0306 4 2019-02-21 true 0001333170 NxStage Medical, Inc. NXTM 0001195852 TOWSE MATTHEW W 350 MERRIMACK STREET LAWRENCE MA 01843 false true false false SVP and Chief Financial Office Common Stock 2019-02-21 4 D false 28396 30 D 0 D Stock Option (Right to Buy) 14.66 2019-02-21 4 D false 60958 0 D 2014-04-10 2024-03-09 Common Stock 60958 0 D Stock Option (Right to Buy) 16.66 2019-02-21 4 D false 65618 0 D 2015-04-03 2025-03-02 Common Stock 65618 0 D Stock Option (Right to Buy) 15.58 2019-02-21 4 D false 89386 0 D 2016-04-09 2026-03-08 Common Stock 89386 0 D Stock Option (Right to Buy) 27.89 2019-02-21 4 D false 49855 0 D 2017-04-09 2027-03-08 Common Stock 49855 0 D Restricted Stock Unit 0 2019-02-21 4 D false 11643 0 D 2018-03-09 2020-03-09 Common Stock 11643 0 D Disposed of under Merger Agreement with Fresenius Medical Care Holdings, Inc. in which all outstanding shares of Issuer's Common Stock were converted into the right to receive $30 per share in cash. This option was canceled in the Merger in exchange for an amount in cash equal to the product of the total number of shares subject to the option multiplied by the excess of the Merger Consideration of $30 per share over the option exercise price. These performance shares were canceled in the Merger in exchange for an amount in cash equal to the product of the total number of performance shares multiplied by the Merger Consideration of $30 per share. /s/ Aras Lapinskas, attorney-in-fact for Matthew Towse 2019-02-25